Literature DB >> 1575766

An investigation of the formation of cytotoxic, protein-reactive and stable metabolites from carbamazepine in vitro.

M Pirmohamed1, N R Kitteringham, T M Guenthner, A M Breckenridge, B K Park.   

Abstract

The formation of chemically reactive metabolites from carbamazepine (CBZ) in the presence of mouse and human liver microsomes has been investigated using cytotoxicity and irreversible binding of radiolabelled compound as quantitative end-points. For comparison, the formation of the stable CBZ-10,11-epoxide (CBZ-10,11-E) has been measured. The formation of the cytotoxic, protein-reactive and stable metabolites of CBZ was increased by induction of the cytochrome P450 enzymes by phenobarbitone and reduced by co-incubation in vitro with ketoconazole (10-250 microM), suggesting that the formation of these metabolites is cytochrome P450 dependent. All human livers tested (N = 6) bioactivated CBZ to a protein-reactive metabolite, the mean covalent binding increasing from 0.08 +/- 0.01% (without NADPH) to 0.27 +/- 0.09% (with NADPH; P less than or equal to 0.05). The formation of the chemically reactive metabolites was reduced by a subphysiological concentration of reduced glutathione (GSH) (500 microM), while ascorbic acid (100 microM) had no effect. Neither compound affected the formation of CBZ-10,11-E. Microsomal epoxide hydrolase (mEH), but not cytosolic epoxide hydrolase, caused a concentration-dependent inhibition of cytotoxicity reaching a maximum of 60% at 100 U of mEH. Covalent binding was also reduced by 60% by 100 U mEH. The separated T- and B-lymphocytes showed no difference in sensitivity when incubated with CBZ and mouse microsomes. The study demonstrates that the balance between activation of CBZ by the cytochrome P450 enzymes to a chemically reactive arene oxide metabolite and its detoxification by mEH and GSH may contribute to individual susceptibility to CBZ idiosyncratic toxicity.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1575766     DOI: 10.1016/0006-2952(92)90696-g

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  10 in total

1.  An interaction between carbamazepine and fluvoxamine.

Authors:  V Martinelli; A Bocchetta; A M Palmas; M Del Zompo
Journal:  Br J Clin Pharmacol       Date:  1993-12       Impact factor: 4.335

Review 2.  Effects of the antifungal agents on oxidative drug metabolism: clinical relevance.

Authors:  K Venkatakrishnan; L L von Moltke; D J Greenblatt
Journal:  Clin Pharmacokinet       Date:  2000-02       Impact factor: 6.447

Review 3.  Role of bioactivation in drug-induced hypersensitivity reactions.

Authors:  Joseph P Sanderson; Dean J Naisbitt; B Kevin Park
Journal:  AAPS J       Date:  2006-02-03       Impact factor: 4.009

Review 4.  Idiosyncratic drug reactions. Metabolic bioactivation as a pathogenic mechanism.

Authors:  M Pirmohamed; S Madden; B K Park
Journal:  Clin Pharmacokinet       Date:  1996-09       Impact factor: 6.447

Review 5.  Genetic factors in the predisposition to drug-induced hypersensitivity reactions.

Authors:  Munir Pirmohamed
Journal:  AAPS J       Date:  2006-02-03       Impact factor: 4.009

6.  The use of transgenic cell lines for evaluating toxic metabolites of carbamazepine.

Authors:  C R Valentine; J L Valentine; J Seng; J Leakey; D Casciano
Journal:  Cell Biol Toxicol       Date:  1996-06       Impact factor: 6.691

Review 7.  The role of active metabolites in drug toxicity.

Authors:  M Pirmohamed; N R Kitteringham; B K Park
Journal:  Drug Saf       Date:  1994-08       Impact factor: 5.606

8.  Lymphocyte microsomal epoxide hydrolase in patients on carbamazepine therapy.

Authors:  M Pirmohamed; R Allott; V J Green; N R Kitteringham; D Chadwick; B K Park
Journal:  Br J Clin Pharmacol       Date:  1994-06       Impact factor: 4.335

9.  Pathways of carbamazepine bioactivation in vitro. III. The role of human cytochrome P450 enzymes in the formation of 2,3-dihydroxycarbamazepine.

Authors:  Robin E Pearce; Wei Lu; Yongqiang Wang; Jack P Uetrecht; Maria Almira Correia; J Steven Leeder
Journal:  Drug Metab Dispos       Date:  2008-05-07       Impact factor: 3.922

10.  Glutathione S-transferase M1 and T1 polymorphisms and the risk of mild hepatotoxicity induced by carbamazepine in a tunisian population study.

Authors:  Chahra Chbili; Anis Hassine; Neila Fathallah; Manel Nouira; Salma Naija; Sofiene Ben Ammou; Saad Saguem
Journal:  BMC Neurol       Date:  2018-03-09       Impact factor: 2.474

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.